natgillin/translations-raw huggingface dataset:
Fenspiride medicines are available as syrup or tablets and used in adults and children from the age of 2 years to relieve cough resulting from lung diseases. 
Zdravila, ki vsebujejo fenspirid, so na voljo v obliki sirupa ali tablet in se uporabljajo za lajšanje kašlja, ki ga povzročajo pljučne bolezni, pri odraslih in otrocih, starejših od dveh let.
This included cases of QT prolongation and torsades de pointes (abnormalities of the heart's electrical activity that may lead to heart rhythm disturbances) in patients using these medicines, results of laboratory studies, data from published literature and stakeholder input. 
Med temi dokazi so bili primeri podaljšanja intervala QT in polimorfna ventrikularna tahikardija („torsades de pointes“, nenormalna električna dejavnost srca, ki lahko povzroči motnje srčnega ritma) pri bolnikih, ki so uporabljali ta zdravila, rezultati laboratorijskih študij, podatki iz objavljene literature ter poročila zainteresiranih skupin.
On 16 May 2019, EMA's safety committee (PRAC) recommended that the marketing authorisations for fenspiride medicines be revoked, so the medicines can no longer be marketed in the EU. 
Odbor za ocenjevanje tveganja na področju farmakovigilance (odbor PRAC) Evropske agencije za zdravila je 16. maja 2019 priporočil ukinitev dovoljenja za promet za zdravila, ki vsebujejo fenspirid, tako da promet s temi zdravili v Evropski uniji ni več mogoč.
• Healthcare professionals should no longer prescribe fenspiride medicines and should advise their patients to stop taking fenspiride medicines. 
• Zdravstveni delavci ne smejo več predpisovati zdravil, ki vsebujejo fenspirid, bolnikom, ki ta zdravila jemljejo, pa morajo jemanje odsvetovati.
At that time, the Pharmacovigilance Risk Assessment Committee (PRAC) recommended that supply of fenspiride medicines be suspended as a precautionary measure while the review was ongoing. 
Takrat je Odbor za ocenjevanje tveganja na področju farmakovigilance (odbor PRAC) kot previdnostni ukrep priporočil, da se zdravila, ki vsebujejo fenspirid, med pregledom začasno umaknejo.
• You should stop taking these medicines and contact your doctor or pharmacist for advice on alternative treatments, if needed. 
• Ta zdravila morate prenehati jemati in se o drugačnem zdravljenju po potrebi posvetovati s svojim zdravnikom ali farmacevtom.
• Cough medicines containing fenspiride will no longer be marketed in the EU because of data showing a risk of sudden, serious heart rhythm problems. 
• Zaradi podatkov, na podlagi katerih je dokazano tveganje za nenadne in resne težave s srčnim ritmom, promet z zdravili proti kašlju, ki vsebujejo fenspirid, v Evropski uniji ne bo več dovoljen.
List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Sanofi-Aventis - Produtos Farmacêuticos, Lda. 
Portugalska Sanofi-Aventis - Produtos Farmacêuticos, Lda.
164,5 mg / 3 ml solution for injection intramuscular use 
164,5 mg / ml raztopina za injiciranje intramuskularna uporaba
Dolokadin einmal täglich prolonged release tablet 
Dolokadin einmal täglich 400 mg tableta s podaljšanim sproščanjem
Empreendimento Lagoas Park, Edifício 7 - 3º Piso 2740-244 Porto Salvo Portugal 
Empreendimento Lagoas Park, Edifício 7 - 3º Piso
Slovak Republic Zentiva k.s. 
Madžarska ZENTIVA k.s.
Flupirtinmaleat Winthrop 400 mg Retardtabletten prolonged release tablet 
Flupirtinmaleat Winthrop mg Retardtabletten
Flupirtinmaleat AbZ 100 mg Kapseln 
Flupirtinmaleat AbZ 100 mg
Flupizen 100 mg tvrdé kapsuly 100 mg 
Flupizen 100 mg tvrdé kapsuly
FLUPIZEN 100 mg capsule 
100 mg kapsula
Trancopal Dolo Suppositorien 150 mg suppository rectal use 
Trancopal Dolo Suppositorien
Flupimal 100 mg Hertkapseln 100 mg 
Flupimal 100 mg Hertkapseln
Katadolon Kinderzäpfchen suppository rectal use 
Katadolon Kinderzäpfchen 75 mg svečka rektalna uporaba
Midas Pharma GmbH Rheinstrasse, 49 55218 Ingelheim Germany 
Portugalska Midas Pharma GmbH Rheinstrasse, 49
Flupsadim 100 mg Hartkapseln 100 mg 
Flupsadim 100 mg Hartkapseln
Miflumal 100 mg Hartkapseln 100 mg 
Miflumal 100 mg Hartkapseln
Fluporol 100 mg Hartkapseln 100 mg 
Fluporol 100 mg Hartkapseln
U 
KG
Flupivil 100 mg Hartkapseln 100 mg 
Flupivil 100 mg Hartkapseln
Flupigil 100 mg Hartkapseln 100 mg 
Flupigil 100 mg Hartkapseln
Flupin 100 mg Hartkapseln 100 mg 
Flupin 100 mg Hartkapseln 100 mg kapsula, trda
Further information can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Dodatne informacije so na voljo tukaj: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
In addition, the Committee questioned the proposed method of sterilisation of the medicine. 
Poleg tega je podvomil o predlagani metodi sterilizacije zdravila.
Sirolimus has been used for several years to prevent organ rejection following a transplant. 
Sirolimus se je več let uporabljal za preprečevanje zavračanja organov po presaditvi.
The inflammation may cause discomfort, pain, blurring of vision, and may lead to partial or complete blindness. 
Vnetje lahko povzroči neprijeten občutek, bolečino in zamegljen vid ter lahko povzroči delno ali popolno slepoto.
The main measure of effectiveness was the number of patients in whom inflammation resolved after 5 months of treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih je bilo vnetje ozdravljeno po petih mesecih zdravljenja.
The data from the clinical study was not sufficient to demonstrate the benefit of Opsiria, particularly in European patients. 
Podatki iz klinične študije niso zadoščali za dokaz koristi zdravila Opsiria, zlasti pri evropskih bolnikih.
Withdrawal of the marketing authorisation application for Opsiria (sirolimus) 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Opsiria (sirolimus)
Withdrawal of the marketing authorisation application for Opsiria (sirolimus) EMA/358774/2016 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Opsiria (sirolimus) EMA/358774/2016
Opsiria was investigated in one main study in 347 patients with non-infectious uveitis. 
Zdravilo Opsiria so proučevali v eni glavni študiji pri 347 bolnikih z neinfektivnim uveitisom.
In this study, Opsiria was not compared with any other treatment. 
V tej študiji zdravila Opsiria niso primerjali z nobenim drugim zdravilom.
Opsiria is a medicine that contains the active substance sirolimus. 
Opsiria je zdravilo, ki vsebuje zdravilno učinkovino sirolimus.
The application was withdrawn after that the CHMP had evaluated the documentation provided by the company and formulated lists of questions. 
Vlogo so umaknili po tem, ko je odbor CHMP ocenil dokumentacijo, ki jo je predložila družba, in oblikoval sezname vprašanj.
On 20 May 2016, Santen Oy officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Opsiria, for the treatment of non-infectious uveitis. 
Družba Santen Oy je 20. maja 2016 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Opsiria, namenjenim zdravljenju neinfektivnega uveitisa.
Since mTOR is involved in the activation and proliferation of T lymphocytes (white blood cells that play a role in inflammation), sirolimus is expected to reduce the inflammation in chronic non-infectious uveitis. 
Ker mTOR sodeluje pri aktivaciji in proliferaciji limfocitov T (belih krvnih celic, ki imajo pomembno vlogo pri vnetju), naj bi sirolimus zmanjšal vnetje pri kroničnem neinfektivnem uveitisu.
After the CHMP had assessed the company's responses to the last round of questions, there were still some unresolved issues. 
Potem ko je ocenil odgovore družbe na zadnja vprašanja, so nekatera vprašanja še vedno ostala nerešena.
In its letter notifying the Agency of the withdrawal of application, the company acknowledged the need to submit additional data on the benefits of Opsiria from an ongoing clinical study. 
V dopisu, v katerem družba agencijo obvešča o umiku vloge, družba priznava nujnost predložitve dodatnih podatkov o koristih zdravila Opsiria iz klinične študije, ki še poteka.
Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had had some concerns and was of the provisional opinion that Opsiria could not have been approved for the treatment of non-infectious uveitis. 
Na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je zastavil odbor CHMP, je ta v času umika izrazil določene zadržke in je začasno menil, da zdravila Opsiria ni mogoče odobriti za zdravljenje neinfektivnega uveitisa.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials using Opsiria. 
Družba je odbor CHMP obvestila, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih zdravila Opsiria.
Opsiria was expected to be used for the treatment of non-infectious uveitis (inflammation of the uvea, the middle layer of the eye) in adults. 
Zdravilo Opsiria naj bi se uporabljalo za zdravljenje infektivnega uveitisa (vnetja uvee, srednjega sloja očesa) pri odraslih.
What is Opsiria? 
Kaj je zdravilo Opsiria?
Opsiria was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 30 August 2011 for the treatment of chronic non-infectious uveitis. 
Zdravilo Opsiria je bilo 30. avgusta 2011 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih boleznih) za zdravljenje kroničnega neinfektivnega uveitisa.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Opsiria did not outweigh its risks. 
Zato je v času umika menil, da koristi zdravila Opsiria ne odtehtajo z njim povezanih tveganj.
What was Opsiria expected to be used for? 
Za kaj naj bi se zdravilo Opsiria uporabljalo?
The active substance in Opsiria, sirolimus, is expected to work by blocking an enzyme called ‘mammalian target of rapamycin' (mTOR). 
Zdravilna učinkovina v zdravilu Opsiria, sirolimus, naj bi delovala z zaviranjem encima, imenovanega „tarča rapamicina pri sesalcih“ (mTOR).
It was to be available as a solution to be injected into the eye. 
Na voljo naj bi bilo v obliki raztopine za injiciranje v oko.
How is Opsiria expected to work? 
Kako naj bi zdravilo Opsiria delovalo?
London, 25 October 2007 EMEA/CHMP/350251/2007 
London, 25. oktober 2007 EMEA/CHMP/350251/2007
The Reference Member State was Germany and the Concerned Member States were Austria, Denmark, Spain, Finland, France, Italy, Luxembourg, Norway, Poland, Portugal, Sweden and United Kingdom. 
Referenčna država članica je bila Nemčija, zadevne države članice pa Avstrija, Danska, Španija, Finska, Francija, Italija, Luksemburg, Norveška, Poljska, Portugalska, Švedska in Združeno kraljestvo.
The Mutual Recognition Procedure started on 24 October 2006. 
Postopek medsebojnega priznavanja se je pričel 24. oktobra 2006.
The Rapporteur was Dr Karl Broich and Co-Rapporteur(s) was Dr Pierre Demolis. 
Poročevalec je bil dr. Karl Broich, soporočevalec pa dr. Pierre Demolis.
A positive opinion was adopted by majority on 19 July 2007. 
Pozitivno mnenje je bilo sprejeto z večino glasov dne 19. julija 2007.
The arbitration procedure started on 26 April 2007 with the adoption of a list of questions. 
Arbitražni postopek se je začel 26. aprila 2007 s sprejetjem seznama vprašanj.
The final opinion was converted into a Decision by the European Commission on 24 October 2007. 
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 24. oktobra 2007.
These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State. 
Omenjene države članice niso mogle doseči soglasja glede medsebojnega priznavanja dovoljenja za promet z zdravilom, ki ga je izdala referenčna država članica.
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III. 
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, povzetek glavnih značilnosti zdravila pa v Dodatku III.
The Marketing Authorisation Holder provided written explanations on 25 May 2007. 
Imetnik dovoljenja za promet z zdravilom je podal pisna pojasnila 25. maja 2007.
During their 16-19 July 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Xeomin, that the objections raised by Finland, France and Italy, should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended. 
Med svojim zasedanjem od 16. do 19. julija 2007 je CHMP na podlagi vseh posredovanih podatkov in znanstvene razprave v okviru Odbora, sprejel mnenje, da je razmerje med tveganji in koristmi za zdravilo Xeomin ugodno, pri čemer ugovori, ki so jih predstavile Finska, Francija in Italija, ne bi smeli preprečiti odobritve dovoljenja za promet z zdravilom, ter da je treba povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo referenčne države članice dopolniti.
On the basis of the questions raised by the Member States, the points to be considered by the CHMP concerned the posology, the repeated administration and safety profile in two Phase III studies. 
Glede na vprašanja, ki so jih izpostavile države članice, je moral CHMP obravnavati zadeve v zvezi z odmerjanjem zdravila, ponavljajočo se uporabo zdravila in varnostni profil zdravila v študijah faze III.
Germany referred the reasons for disagreement to the EMEA on 29 March 2007. 
Nemčija je Evropski agenciji za zdravila dne 29. marca 2007 predložila razloge za nesoglasje.
Merz Pharmaceuticals GmbH submitted applications for mutual recognition of Xeomin, 100 LD50 units powder for solution for injection, on the basis of the marketing authorisation granted by Germany on 31 May 2005. 
Podjetje Merz Pharmaceuticals GmbH je predložilo vloge za postopek medsebojnega priznavanja zdravila Xeomin, 100 LD50 enot, prašek za pripravo raztopine za injiciranje na osnovi dovoljenja za promet z zdravilom, ki ga je izdala Nemčija dne 31. maja 2005.
Xeomin, 100 LD50 units powder for solution for injection, is indicated for the symptomatic management of blepharospasm and cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adults. 
Zdravilo Xeomin, 100 LD50 enot, prašek za pripravo raztopine za injiciranje je indiciran za simptomatično zdravljenje blefarospazmov in cervikalne distonije pretežno rotacijske oblike (spastični tortikolis) pri odraslih.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Xeomin International Non-Proprietary Name (INN): Clostridium botulinum neurotoxin type A 
Xeomin Mednarodno nelastniško ime (INN): Nevrotoksin bakterije Clostridium botulinum tipa A
The tablets should be taken with food. 
Tablete je treba jemati sočasno s hrano.
The recommended dose is 4 tablets once a day for the first 2 weeks and then 2 tablets taken 3 times a week for the next 22 weeks. 
Priporočeni odmerek je 4 tablete enkrat na dan prva 2 tedna, nadaljnjih 22 tednov pa 2 tableti 3-krat na teden.
The company will also provide longer term safety data on the medicine. 
Prav tako bo predložila tudi dolgoročnejše podatke o varnosti zdravila.
The medicine is available as 100 mg tablets. 
Zdravilo je na voljo v obliki 100-miligramskih tablet.
This means that there is more evidence to come about the medicine, which the company is required to provide. 
To pomeni, da se pričakujejo dodatni dokazi o zdravilu, ki jih mora zagotoviti družba.
This is a summary of the European public assessment report (EPAR) for Sirturo. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Sirturo.
Tuberculosis is an infection caused by the bacterium Mycobacterium tuberculosis. 
Tuberkuloza je okužba, ki jo povzroča bakterija Mycobacterium tuberculosis.
Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary. 
Evropska agencija za zdravila bo vsako leto ponovno pregledala vse nove razpoložljive podatke in posodobila povzetek glavnih značilnosti zdravila, če bo to potrebno.
In addition, it is recommended that patients are directly observed by a healthcare professional as they take the medicine. 
Poleg tega je priporočljivo, da bolnike med jemanjem zdravila neposredno nadzoruje zdravstveni delavec.
What measures are being taken to ensure the safe and effective use of Sirturo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Sirturo?
It is given when combinations without Sirturo cannot be used, either because the disease is resistant to them or because of their side effects. 
Uporablja se, kadar kombinacij brez zdravila Sirturo ni mogoče uporabiti bodisi zaradi odpornosti bolezni proti tem kombinacijam ali zaradi njihovih neželenih učinkov.
Without the ability to generate energy, the bacteria die and the patient's condition can start to improve. 
Če bakterije ne morejo več pridobivati energije, odmrejo, bolnikovo stanje pa se začne izboljševati.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Sirturo's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Sirturo večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The summary of the opinion of the Committee for Orphan Medicinal Products for Sirturo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Sirturo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
A risk management plan has been developed to ensure that Sirturo is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Sirturo je bil pripravljen načrt obvladovanja tveganj.
Although an analysis of these deaths did not support the conclusion that they were caused by Sirturo, the CHMP has required the company to provide more information from a long-term follow-up study to allay any concerns. 
Čeprav analiza teh primerov ni podprla zaključka, da so bile smrti posledica uporabe zdravila Sirturo, je odbor CHMP zahteval, da družba pridobi več podatkov v dolgoročni študiji spremljanja, da se odpravijo morebitni zadržki.
It is not intended to provide practical advice on how to use Sirturo. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The most common side effects with Sirturo (which may affect more than 1 in 10 people) are headache, dizziness, nausea (feeling sick), vomiting, and arthralgia (joint pain). 
Najpogostejši neželeni učinki zdravila Sirturo (ki lahko prizadenejo več kot 1 osebo od 10) so glavobol, omotica, navzea (slabost), bruhanje in artralgija (bolečine v sklepih).
Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare', and Sirturo was designated an ‘orphan medicine' (a medicine used in rare diseases) on 26 August 2005. 
Ker je bolnikov s tuberkulozo v EU malo, velja ta bolezen za redko, zato je bilo zdravilo Sirturo 26. avgusta 2005 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Other information about Sirturo 
Druge informacije o zdravilu Sirturo
The study showed that after 24 weeks, 79% of the patients given Sirturo (52 out of 66 patients) tested negative for the bacteria in the sputum (phlegm) compared with 58% of patients given placebo (38 out of 66 patients). 
Študija je pokazala, da je bil po 24 tednih test na prisotnost bakterij v sputumu (izpljunku) negativen pri 79 % (52 od 66) bolnikov, ki so prejemali zdravilo Sirturo, v primerjavi z 58 % (38 od 66) bolnikov, ki so prejemali placebo.
The Committee highlighted the need for new medicines to treat multi-drug resistant tuberculosis and noted that Sirturo was the first of a new class of medicines for which cross-resistance with other medicines had not yet been seen. 
Odbor je poudaril potrebo po novih zdravilih za zdravljenje tuberkuloze, odporne proti več zdravilom, in izpostavil, da je zdravilo Sirturo prvo zdravilo iz nove skupine, pri katerem še niso opazili navzkrižne odpornosti z drugimi zdravili.
Since Sirturo has been granted a conditional approval, the company that markets Sirturo will provide additional data on the medicine's benefits and safety when used with different combinations of medicines. 
Ker je zdravilo Sirturo pridobilo pogojno dovoljenje za promet, bo družba, ki ga trži, zagotovila dodatne podatke o koristih in varnosti zdravila pri njegovi uporabi skupaj z različnimi kombinacijami zdravil.
The active substance in Sirturo, bedaquiline, works by specifically blocking an enzyme inside the M. tuberculosis bacteria called ATP synthase, which the bacteria need to generate energy. 
Zdravilna učinkovina v zdravilu Sirturo, bedakilin, deluje tako, da specifično zavira encim v bakterijah M. tuberculosis, imenovan ATP-sintaza, ki ga bakterije potrebujejo za pridobivanje energije.
Sirturo increased the number of patients who tested negative for the tuberculosis bacteria and shortened the average time it took to clear the bacteria from the sputum. 
Zdravilo Sirturo je povečalo število bolnikov, pri katerih je bil test na prisotnost bakterij tuberkuloze negativen, in skrajšalo povprečen čas, ki je bil potreben za to, da so se bakterije izločile iz sputuma.
The full EPAR and risk management plan summary for Sirturo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Sirturo sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What benefits of Sirturo have been shown in studies? 
Kakšne koristi je zdravilo Sirturo izkazalo v študijah?
With regard to safety, the side effects reported in the Sirturo group in the main study were not markedly different from those in the placebo group, though there were higher levels of liver enzymes and some reports of alterations in the heart's electrical activity (known as prolonged QT interval). 
Kar zadeva varnost, se neželeni učinki, o katerih so v glavni študiji poročali v skupini bolnikov, ki so jemali zdravilo Sirturo, niso bistveno razlikovali od tistih, ki so jih opazili v skupini, zdravljeni s placebom, vendar pa so zabeležili višje ravni jetrnih encimov in nekaj poročil o spremembah v električni aktivnosti srca (t. i. podaljšanju intervala QT).
For more information about treatment with Sirturo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Sirturo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Cross-resistance is when bacteria develop resistance to a medicine after being exposed to another one, which is often the case with multi-drug resistant tuberculosis. 
Navzkrižna odpornost pomeni, da bakterije razvijejo odpornost proti določenemu zdravilu, potem ko so bile izpostavljene drugemu zdravilu, kar se pogosto zgodi pri tuberkulozi, odporni proti več zdravilom.
What are the risks associated with Sirturo? 
Kakšna tveganja so povezana z zdravilom Sirturo?